HUE035052T2 - Bakteriális gazdatörzs, amely rekombináns DSBC-t expresszál és csökkentett TSP-aktivitása van - Google Patents
Bakteriális gazdatörzs, amely rekombináns DSBC-t expresszál és csökkentett TSP-aktivitása van Download PDFInfo
- Publication number
- HUE035052T2 HUE035052T2 HUE10734333A HUE10734333A HUE035052T2 HU E035052 T2 HUE035052 T2 HU E035052T2 HU E10734333 A HUE10734333 A HU E10734333A HU E10734333 A HUE10734333 A HU E10734333A HU E035052 T2 HUE035052 T2 HU E035052T2
- Authority
- HU
- Hungary
- Prior art keywords
- allosteric
- ssr
- binding
- fgfr
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (5)
- BAKTERIÁLIS GAZÖATÖRZS« AMELY REKOMBINÁNS ÖS8C-T EXPRESSZÁL ÉS CSÖKKENTETT TSP«AKTIVITÁSA VAN Sza bad a hm igény po n tok í, Allosztéríkus inhibitor-kötőhely alkalmazása Í GÉR nem polimer, kisruolekulás, 1000 Da nái kisebb snolekuíaíőmegú inhibitorainak szkrinelésére, ahol az allosztéríkus inhibitor-kötőhely SEQ it) NO. I szerinti szekvenciából vagy SEQ 10 NO. 1 szeriüli szekvenciával legalább 70%-ban, 80%-ban, 90%-ban vagy 95%-ban homológ szekvenciából áll.
- 2. Eljárás feltételezett allosztéríkus inhibitor-kötőhely azonosítására FORE c-xtntcelluláris doménjében, amely tartalmazza a kővetkezőket; az exiracelluláris doménben frusztrált doménekre történő szkríneídst egy másodlagos fehérjeszerkezetet predikiáló program alkalmazásával olyan döntenek vagy fragmenseik azonosítására az exiracelluláris doménben, amelyek hajlamosak báta-redő aifa-héítx átmenetre, vagy amelyeknek olyan szerkezetük van, amelyet a másodlagos fehérjeszerkezetet predikiáló program a valós, kristályosítással és rőnlgenűitTntkeióval meghatározóit szerkezettel ellenttriotídónak prediktái, .és az így azonosított dóménak vagy fragmensek kiválasztását további szkrtnefésre a feltételezett bthlhi-torhely funkciójának megerősítésére vcgyületek, így kis molekulák, kis peptidek, pepiidomhnetikumok, anlites-lek vagy nanotesték tervezésével, amelyek kötődnek a helyhez, és amelyekkel az allosztéríkus mhibitortunkeió tesztelhető,
- 3, A 2, igénypont szerimi eljárás, ahoi az allosztéríkus kötőhely ínhibitorfunkciója a szabályozóit szignál-reakeiőutak szelektív gátlása.
- 4, Eljárás iirozínk máz-receptor extracelluláris doménjében allosztéríkus inhibitorhelyhez RTK-kötődés nem-polimer, kismolekuíás, allosztérikus inhibitorának azonosítására, amely tartalmazza a kővetkezőket: RTK allosztétikus kötőhelyének érinikeztetését a kismolekuíás, allosztéríkus inhibitorként feltételezett ve-gyülettel, és a tirozmkmáz-receptor aktlváíásátói/gátlásáíól lüggo, kél különböző, szabályozott reakcióid: által indukált legalább két különböző riporter állapotában bekövetkező változás összehssouíííását, ahol a nem-polimer, kismolekuíás inhibitor molekulatömege kisebb, mint i 000 Da,
- 5. A 4, igénypont szerinti eljárás, ttboi allosztéríkus inhibitort azonosítunk, amikor a receptor ligandkőfö donténjéhez kötődő Ügand jelenlétében legalább egy szabályozott reakcióüt gátolt, miközben legalább egy má-sík, szabályozott reakcióút nem érintett. ő. .A 4, vagy 5 , igénypont szerinti eljárá;;, amelyben a iirozinkÍnáz-inhíbhor FGRP, 7. A 6. igénypont szerinti eljárás, ahol az EGFR a következők egyikeként választott: FGFR-1, FGFR-2. FGFÏG3 vagy FGFR-4. S. A 4-7. igénypontok bármelyike szerinti eljárás RTK allosztéríkus inhibitorának azonosítására. ahol a két különböző, szabályozott reakcióul megfelel az. ERK1/2 szígriái-reakcíóútnnk és a PI.Cv szignál-reakcióütnak.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09290537A EP2270043A1 (en) | 2009-07-03 | 2009-07-03 | Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE035052T2 true HUE035052T2 (hu) | 2018-05-02 |
Family
ID=41137351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE10734333A HUE035052T2 (hu) | 2009-07-03 | 2010-07-02 | Bakteriális gazdatörzs, amely rekombináns DSBC-t expresszál és csökkentett TSP-aktivitása van |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9234025B2 (hu) |
| EP (2) | EP2270043A1 (hu) |
| JP (2) | JP6255156B2 (hu) |
| KR (1) | KR101828092B1 (hu) |
| CN (1) | CN102596991B (hu) |
| AU (1) | AU2010267590B2 (hu) |
| BR (1) | BR112012000029B8 (hu) |
| CA (1) | CA2766972C (hu) |
| DK (1) | DK2448964T3 (hu) |
| ES (1) | ES2631452T3 (hu) |
| HU (1) | HUE035052T2 (hu) |
| IL (1) | IL217155B (hu) |
| MX (1) | MX345715B (hu) |
| MY (1) | MY158993A (hu) |
| RU (1) | RU2604805C2 (hu) |
| SG (2) | SG177427A1 (hu) |
| WO (1) | WO2011001413A1 (hu) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2985258A1 (fr) * | 2011-12-28 | 2013-07-05 | Sanofi Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
| AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| WO2015127242A1 (en) * | 2014-02-21 | 2015-08-27 | President And Fellows Of Harvard College | De novo design of allosteric proteins |
| KR102344105B1 (ko) | 2014-08-18 | 2021-12-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 모노시클릭 피리딘 유도체의 염 및 이의 결정 |
| WO2018081534A1 (en) | 2016-10-28 | 2018-05-03 | President And Fellows Of Harvard College | Assay for exo-site binding molecules |
| CN111107881A (zh) * | 2017-06-22 | 2020-05-05 | 密执安州立大学董事会 | 成纤维细胞生长因子受体2特异性肽试剂和方法 |
| US11548931B2 (en) | 2017-11-16 | 2023-01-10 | Xl-Protein Gmbh | PASylated VEGFR/PDGFR fusion proteins and their use in therapy |
| MX2020008610A (es) | 2018-03-28 | 2020-09-21 | Eisai R&D Man Co Ltd | Agente terapeutico para carcinoma hepatocelular. |
| CN113651662B (zh) * | 2020-12-31 | 2023-10-27 | 复旦大学附属华山医院 | 一种靶向fgfr的新型肿瘤pet分子探针及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030004397A (ko) * | 2000-05-11 | 2003-01-14 | 와이어쓰 | Ｇ-단백질(ｒｇｓ４)의 구조 및 이를 사용한 효능제 및길항제의 동정 방법 |
| US7393656B2 (en) * | 2001-07-10 | 2008-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for risk stratification |
| FR2838123B1 (fr) * | 2002-04-04 | 2005-06-10 | Sanofi Synthelabo | Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf |
| US7083933B1 (en) * | 2003-05-09 | 2006-08-01 | Prosidion Limited | Methods for identification of modulators of OSGPR116 activity |
| CA2550245A1 (en) * | 2003-12-19 | 2005-07-21 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
| FR2865934B1 (fr) * | 2004-02-05 | 2006-05-05 | Sanofi Synthelabo | Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne |
| NZ551832A (en) * | 2004-06-09 | 2010-01-29 | Univ Edinburgh | Neural stem cells |
| EP1885708A2 (en) * | 2005-04-15 | 2008-02-13 | Board of Trustees of Michigan State University | Gpcr modulators |
| FR2896247B1 (fr) | 2006-01-13 | 2008-02-29 | Sanofi Aventis Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
| EP1891955A1 (en) * | 2006-07-24 | 2008-02-27 | Sanofi-Aventis | Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases |
-
2009
- 2009-07-03 EP EP09290537A patent/EP2270043A1/en not_active Withdrawn
-
2010
- 2010-07-02 SG SG2011097284A patent/SG177427A1/en unknown
- 2010-07-02 MX MX2012000298A patent/MX345715B/es active IP Right Grant
- 2010-07-02 EP EP10734333.7A patent/EP2448964B1/en active Active
- 2010-07-02 ES ES10734333.7T patent/ES2631452T3/es active Active
- 2010-07-02 JP JP2012518145A patent/JP6255156B2/ja active Active
- 2010-07-02 RU RU2012103542/10A patent/RU2604805C2/ru active
- 2010-07-02 WO PCT/IB2010/053054 patent/WO2011001413A1/en active Application Filing
- 2010-07-02 AU AU2010267590A patent/AU2010267590B2/en active Active
- 2010-07-02 MY MYPI2011006390A patent/MY158993A/en unknown
- 2010-07-02 HU HUE10734333A patent/HUE035052T2/hu unknown
- 2010-07-02 CN CN201080039710.5A patent/CN102596991B/zh active Active
- 2010-07-02 KR KR1020127002920A patent/KR101828092B1/ko active IP Right Grant
- 2010-07-02 SG SG10201403778TA patent/SG10201403778TA/en unknown
- 2010-07-02 CA CA2766972A patent/CA2766972C/en active Active
- 2010-07-02 US US13/379,822 patent/US9234025B2/en active Active
- 2010-07-02 DK DK10734333.7T patent/DK2448964T3/en active
- 2010-07-02 BR BR112012000029A patent/BR112012000029B8/pt active IP Right Grant
-
2011
- 2011-12-22 IL IL217155A patent/IL217155B/en active IP Right Grant
-
2015
- 2015-11-30 US US14/954,301 patent/US20160193192A1/en not_active Abandoned
-
2016
- 2016-10-07 JP JP2016198682A patent/JP2017036305A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK2448964T3 (en) | 2017-07-24 |
| SG10201403778TA (en) | 2014-10-30 |
| EP2270043A1 (en) | 2011-01-05 |
| EP2448964B1 (en) | 2017-04-12 |
| CN102596991A (zh) | 2012-07-18 |
| JP2012532121A (ja) | 2012-12-13 |
| CN102596991B (zh) | 2016-06-08 |
| MX345715B (es) | 2017-02-13 |
| AU2010267590A1 (en) | 2012-02-02 |
| MX2012000298A (es) | 2013-05-30 |
| CA2766972A1 (en) | 2011-01-06 |
| IL217155B (en) | 2019-01-31 |
| MY158993A (en) | 2016-11-30 |
| EP2448964A1 (en) | 2012-05-09 |
| WO2011001413A1 (en) | 2011-01-06 |
| KR20120093146A (ko) | 2012-08-22 |
| US20160193192A1 (en) | 2016-07-07 |
| RU2012103542A (ru) | 2013-08-10 |
| US20120094864A1 (en) | 2012-04-19 |
| IL217155A0 (en) | 2012-02-29 |
| JP2017036305A (ja) | 2017-02-16 |
| ES2631452T3 (es) | 2017-08-31 |
| BR112012000029B1 (pt) | 2020-12-08 |
| BR112012000029B8 (pt) | 2021-05-25 |
| SG177427A1 (en) | 2012-02-28 |
| KR101828092B1 (ko) | 2018-02-09 |
| US9234025B2 (en) | 2016-01-12 |
| JP6255156B2 (ja) | 2017-12-27 |
| AU2010267590B2 (en) | 2016-08-04 |
| RU2604805C2 (ru) | 2016-12-10 |
| CA2766972C (en) | 2019-03-05 |
| BR112012000029A2 (pt) | 2016-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010267590B2 (en) | Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor | |
| Gray et al. | Identification of a binding site on the type II activin receptor for activin and inhibin | |
| Rowlinson et al. | An agonist-induced conformational change in the growth hormone receptor determines the choice of signalling pathway | |
| Gao et al. | A floor-plate extracellular protein-protein interaction screen identifies Draxin as a secreted Netrin-1 antagonist | |
| Seong et al. | NM23-H1 tumor suppressor physically interacts with serine-threonine kinase receptor-associated protein, a transforming growth factor-β (TGF-β) receptor-interacting protein, and negatively regulates TGF-β signaling | |
| Najib et al. | A switch of G protein-coupled receptor binding preference from phosphoinositide 3-kinase (PI3K)–p85 to filamin A negatively controls the PI3K pathway | |
| Franco et al. | Structural basis of the transmembrane domain dimerization and rotation in the activation mechanism of the TRKA receptor by nerve growth factor | |
| Cash et al. | Characterization of follistatin-type domains and their contribution to myostatin and activin A antagonism | |
| Klaavuniemi et al. | Zasp/Cypher internal ZM-motif containing fragments are sufficient to co-localize with α-actinin—Analysis of patient mutations | |
| Palmerini et al. | Drosophila TNFRs Grindelwald and Wengen bind Eiger with different affinities and promote distinct cellular functions | |
| Ahmed et al. | Direct binding of Grb2 SH3 domain to FGFR2 regulates SHP2 function | |
| Wang et al. | A homeo-interaction sequence in the ectodomain of the fibroblast growth factor receptor | |
| Ivanisevic et al. | TrkA receptor “hot spots” for binding of NT-3 as a heterologous ligand | |
| McCoy et al. | Crystal structure of the WFIKKN2 follistatin domain reveals insight into how it inhibits growth differentiation factor 8 (GDF8) and GDF11 | |
| Scotton et al. | Activation of muscle-specific receptor tyrosine kinase and binding to dystroglycan are regulated by alternative mRNA splicing of agrin | |
| Yuan et al. | The Ran binding protein RanBPM interacts with TrkA receptor | |
| Gipson et al. | Characterization of the different oligomeric states of the DAN family antagonists SOSTDC1 and SOST | |
| You et al. | ShcD interacts with TrkB via its PTB and SH2 domains and regulates BDNF-induced MAPK activation | |
| Zhao et al. | A comprehensive functional analysis on the pathogenesis of novel TSPAN12 and NDP variants in familial exudative vitreoretinopathy | |
| Dye et al. | hShroom1 links a membrane bound protein to the actin cytoskeleton | |
| Just et al. | Understanding amylin receptors | |
| Murray | J. Biol. Chem.-2019-McCoy-jbc. RA118. 005831. pdf | |
| Ni et al. | A profile of the residues in the second extracellular loop that are critical for ligand recognition of human prostacyclin receptor | |
| Zhao | The Role of Intracellular Domains in KCNH Potassium Channel Gating | |
| Yadav et al. | Novel Tumor Suppressor PTPRA Regulates GDNF-Dependent RET Signaling and Inhibits the RET Mutant MEN2A Oncogenic Potential |